Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.
With more than 60 years of experience in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
As a leader in oncology, Servier is committed to finding solutions that will address today’s challenges. The company is pioneering the science behind IDH mutations, bringing new therapeutic options to patients, and investing in people, infrastructure and innovation at a time when most industry peers are scaling back. In oncology, Servier is also targeting apoptosis in immuno-oncology and cell metabolism.
Servier has experienced exponential growth since opening its doors in the United States in 2018, quadrupling its oncology portfolio from one to five assets in less than four years. The company’s oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, with 25 oncology assets at varying stages of clinical development, and 20 research projects across the entire spectrum of disease and in a variety of tumor types.
In the past year, Servier has received two ground breaking FDA approvals, including the company’s entrance into solid tumors with cholangiocarcinoma. Additionally, Servier is expanding its pipeline with seven potential additions, including two new products in solid tumors, expecting to reach $1 billion in organic growth and receive three additional FDA approvals in the next five years.
Servier’s ongoing success in the U.S., both clinically and commercially, has allowed the company to expand its footprint in the Boston Seaport with the launch of a new office and $10 million-dollar state-of-the-art lab space.
Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies to patients.
More information: www.servier.com
